This article is more than 5 years old. Information may no longer be current.
AstraZeneca’s ZS-9 reduces serum potassium levels in patients with hyperkalemia
Click Here to Manage Email Alerts
New Orleans - AstraZeneca’s investigational hyperkalemia treatment sodium zirconium cyclosilicate (ZS-9) reduced serum potassium levels in patients with hyperkalemia and maintained blood serum potassium at normal levels (normokalemia) for up to 12 months, according to data from a Phase 3 open label trial examining long-term safety and efficacy. The data was presented by lead investigator Steven Fishbane, MD, from Hofstra Northwell School of Medicine, at the American Society of Nephrology's Kidney Week 2017.
Most of the patients achieved normokalaemia (99.3%; n=746/751) and were eligible for the extended one-year maintenance phase. Mean potassium levels of ≤5.1 or ≤5.5mEq/L were maintained during the extended phase, in 88% and 99% of patients respectively from month three to month 12.
Common adverse effects (among ≥5% of patients) reported during the extended dosing phase were hypertension, peripheral edema, urinary tract infection, nausea, constipation, anemia and upper respiratory tract infection. - Rebecca Zumoff